— · —
OPTH (OPTH) Stock
$4.67
-1.89%
—: OPTH
—
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
3 Psychedelic Stocks With Potential Clinical Trial Catalysts
Simply Wall St. · Jul 10, 2026
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive · Jul 6, 2026
Optimi Health Makes Third Commercial Shipment of Psilocybin for Treatment-Resistant Depression to Australia
MT Newswires · Jun 29, 2026
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
PR Newswire · Jun 29, 2026
Optimi Health Completes Third Psilocybin Export to Australia
MT Newswires · Jun 29, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.60%
Institutions Held8.78%
Institutions Float Held8.83%
Peer Comparison
About OPTH
OPTH is led by CEO Dane Stevens, employs 6 people, headquartered in CA, publicly traded since 2026.
OPTH stock trades at $4.67 with a market capitalization of $15.04M. The stock is valued at a price-to-earnings (P/E) ratio of -5.04, price-to-book of 2.70, price-to-sales of 139.97. Over the past 52 weeks the stock has ranged between $4.00 and $6.40, and currently trades 27.0% below its 52-week high.
On profitability, OPTH generates a return on equity (ROE) of -57.14%, return on capital employed of -83.33%, an operating margin of -24.02%, a net profit margin of -20.70%.